PFAS exposure causes elevated liver enzymes and fatty liver changes.

Evidence from large-scale epidemiological studies and mechanistic research strongly supports the association between per- and polyfluoroalkyl substances (PFAS) exposure and markers of liver injury, specifically elevated liver enzymes and fatty liver-type changes.

Clinical evidence of hepatic injury

Data from long-term cohorts, including the NHANES (2003–2018) and the C8 Health Project, consistently show that serum concentrations of PFAS—particularly perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS)—are positively correlated with elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

• Liver Enzyme Elevation: Studies indicate a 6% to 16% increase in the risk of above-normal ALT levels across PFOA exposure quintiles.
• Steatosis Risk: PFAS exposure is associated with a significantly increased risk of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), with odds ratios ranging from 1.39 to 2.06 depending on the specific congener.
• Fibrosis Correlation: While associations with simple steatosis can vary, stronger correlations have been observed between PFAS exposure and markers of hepatic fibrosis, indicating a potential for disease progression.

Mechanistic pathways: Metabolism and oxidative stress

The liver injury observed following PFAS exposure is driven by a well-defined synergy between metabolic disruption and cellular stress.

• Oxidative Stress: PFAS compounds trigger the overproduction of reactive oxygen species (ROS) and deplete essential antioxidant defenses, such as glutathione (GSH) and superoxide dismutase (SOD). This leads to increased lipid peroxidation, often measured via markers like malondialdehyde (MDA).
• Metabolic Disruption: PFAS act as potent metabolic disruptors by activating nuclear receptors, most notably PPAR-α. This activation dysregulates genes responsible for lipid synthesis and catabolism.
• Lipogenesis: Exposure upregulates de novo lipogenesis through pathways involving SREBP1 and PERK, leading to the accumulation of triglycerides and the development of fatty liver changes (steatosis).

Bottom line

PFAS exposure is a recognized risk factor for liver dysfunction, manifesting as elevated ALT/AST and hepatic steatosis. These changes are primarily driven by PPAR-α-mediated lipid disruption and significant oxidative stress, which together promote hepatocellular injury and metabolic imbalance.